Exposure to concentrated ambient particles does not affect vascular function in patients with coronary heart disease

Citation for published version:

Digital Object Identifier (DOI):
10.1289/ehp.11016

Link:
Link to publication record in Edinburgh Research Explorer

Document Version:
Publisher's PDF, also known as Version of record

Published in:
Environmental Health Perspectives

General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer content complies with UK legislation. If you believe that the public display of this file breaches copyright please contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and investigate your claim.
Exposure to Concentrated Ambient Particles Does Not Affect Vascular Function in Patients with Coronary Heart Disease

Nicholas L. Mills,1 Simon D. Robinson,1 Paul H. B. Fokkens,2 Daan L. A. C. Leseman,2 Mark R. Miller,1 David Anderson,3 Evelyn J. Freney,4 Mathew R. Heal,4 Robert J. Donovan,4 Anders Blomberg,5 Thomas Sandström,5 William MacNee,3 Nicholas A. Boon,1 Ken Donaldson,3 David E. Newby,1 and Flemming R. Cassee2

1Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom; 2National Institute for Public Health and the Environment (RIVM), Bilthoven, Netherlands; 3EleGI Colt Laboratory, Centre for Inflammation Research, University of Edinburgh, Edinburgh, United Kingdom; 4School of Chemistry, University of Edinburgh, Edinburgh, United Kingdom; 5Department of Respiratory Medicine and Allergy, Umeå University, Umeå, Sweden

Evidence accumulated over more than 50 years of epidemiologic and clinical research has established the adverse effects of air pollution on human health. The London smog of December 1952 caused > 4,000 excess deaths (Ministry of Health 1954); in spite of the dramatic decreases in levels of air pollution that have been achieved since then, the association between air pollution and cardiorespiratory morbidity and mortality persists (Anderson et al. 1996; Dockery et al. 1993; Pope et al. 2002). These associations are strongest for fine particulate matter (PM < 2.5 µm in aerodynamic diameter; PM2.5), and the majority of excess deaths are due to cardiovascular events (Pope 2000). Despite the strength of the epidemiologic evidence and the emergence of promising hypotheses, the constituents and biological mechanisms responsible for the cardiovascular effects of air pollution are only beginning to emerge.

Exposure to particulate air pollution has been associated with exercise-induced myocardial ischemia in patients with coronary heart disease (Pekkanen et al. 2002) and with triggering acute myocardial infarction (Peters et al. 2001a). These findings are limited by exposure misclassification, the effect of potential confounding environmental and social factors, and the lack of mechanistic data (Stone 2004). Controlled exposures of air pollutants can help address these shortcomings by providing a precisely defined exposure in a regulated environment that facilitates investigation with validated biomarkers and surrogate measures of cardiovascular health. Using a carefully characterized exposure system, we previously showed that exposure to dilute diesel exhaust causes lung inflammation (Salvi et al. 1999), depletion of airway antioxidant defenses (Behndig et al. 2006), and impairment of vascular and fibrinolytic function (Mills et al. 2005). Moreover, we recently described ischemic and thrombotic effects in patients with coronary heart disease (Mills et al. 2007). Although controlled exposure to diesel exhaust is an excellent model for studying the effects of pure combustion-derived air pollution, we acknowledge that ambient air pollution contains a range of particulate pollutants from a variety of atmospheric sources. In the last few years, technology has been developed that can deliver a continuous flow of air in which the concentration of ambient particulate matter is increased 10- to 60-fold in real-time (Kim et al. 2001; Sioutas et al. 1995, 1997). The principle advantage of these concentrations is that they provide real-world inhalation exposures under controlled conditions.

In previous studies, exposure to fine (0.15–2.5 µm in aerodynamic diameter) concentrated ambient particles (CAPs) induced mild pulmonary inflammation in healthy adults (Ghio et al. 2002) and increased heart rate variability in the elderly (Devlin et al. 2003) and in asthmatic and healthy younger adults (Gong et al. 2003). Furthermore, exposure to fine CAPs plus ozone causes peripheral arterial vasoconstriction (Brook et al. 2002) and decreases in arterial pressure (Urch et al. 2005). To date, no studies have addressed the effects of exposure to CAPs in isolation on vascular function, nor have any previous studies assessed the effects of these exposures in an at-risk population of patients with established coronary heart disease. In the present study, we included the ultrafine (particles < 0.15 µm in aerodynamic diameter) fraction of PM. We aimed to assess the effects of a 2-h exposure to fine and ultrafine CAPs on peripheral vascular function and fibrinolytic function in
patients with stable coronary heart disease and
in age-matched healthy controls.

Materials and Methods

Subjects. Twelve male patients with stable
 coronary heart disease and 12 age-matched,
 male, nonsmoking volunteers participated in
 these studies, which were performed with the
 approval of the local research ethics committee,
 in accordance with the Declaration of Helsinki
 (World Medical Association 2000), and the
 written informed consent of all volunteers.

Patients with previous myocardial infarction
 or stable angina treated by angioplasty and
 stenting (> 6 months before enrollment) were
 recruited from the outpatient clinic in the
 cardiology department at the Royal
 Infirmary Edinburgh (Edinburgh, Scotland,
 UK). Patients with symptomatic angina pec-
 toris (Canadian Cardiovascular Society grade
 ≥ 2; Campeau et al. 1976) or those unable to
 achieve stage 2 of the Bruce protocol (Bruce
 1971) were excluded from the study. Similarly,
 we excluded any patients with a
 history of arrhythmia, diabetes mellitus,
 uncontrolled hypertension, renal or hepatic
 failure, or unstable coronary disease (acute
 coronary syndrome or unstable symptoms
 within 3 months). Matched control subjects
 were not taking regular medication and had
 no previous history of coronary artery disease,
 and they were not taking regular medication
 and had no clinical evidence of atherosclerotic
 vascular disease, diabetes mellitus, hypertension,
 or renal or hepatic failure.

In both groups, current smokers and
 those with asthma, significant occupational
 exposure to air pollution, or an intercurrent
 illness were excluded from the study. All sub-
 jects had normal lung function as measured
 by spirometry, and none of them reported
 symptoms of respiratory tract infection dur-
 ing the study or in the preceding 6 weeks.

Study design. Subjects attended the clinic
 on two occasions at least 2 weeks apart and
 received CAPs or filtered air in a randomized,
 double-blind cross-over design. Each subject
 was exposed for 2 hr in a specially built
 whole-body exposure chamber. During each
 exposure subjects performed moderate exer-
 cise (minute ventilation 25 L/min/m²) on a
 bicycle ergometer that was alternated with rest
 periods at 15-min intervals.

Based on previous exposure (Mills et al.
 2005) and systemic inflammatory (Salvi et al.
 1999) studies, we performed vascular assess-
 ments 6–8 hr after CAPs or filtered air expo-
 sure. All subjects abstained from alcohol for
 24 hr and from food and caffeine-containing
 drinks for at least 4 hr before each vascular
 study. Studies were carried out in a quiet, tem-
 perature-controlled room maintained at
 22–24°C with subjects supine. All subjects
 remained indoors between the exposure and the
 vascular assessment to minimize additional
 exposure to particulate air pollution.

Concentrated ambient particle exposures
 and characterization. We used a Versatile
 Aerosol Concentration Enrichment System
 (VACES) concentrator (Kim et al. 2001),
 within a Mobile Ambient Particle Con-
 centrator Exposure Laboratory (MAPCEL) to
deliver exposures to concentrated CAPs and fil-
 tered air. The CAPs were derived from an
 urban background site outside the Royal
 Infirmary Edinburgh (Ordnance Survey Grid
 Reference, NT 289 703) approximately
 6 miles from the center of Edinburgh. A bus
 route passed adjacent to the MAPCEL, and an
 arterial city route was located a few hundred
 meters away. To maximize differences in expo-
 sure and minimize the influence of ambient
 pollution, most CAPs exposures were con-
 ducted when ambient pollution levels were
 high. On the day of the first exposure, the
 MAPCEL technicians made a considered judg-
 ment as to whether atmospheric conditions
 were better suited to conducting a CAPs or fil-
tered air exposure, and subjects were random-
 ized accordingly. The study investigators and
 staff remained blinded to exposure allocation
 throughout the study.

A schematic diagram of the MAPCEL and
 VACES used to deliver CAPs and filtered air to
 human subjects is given in Figure 1. Incoming
 ambient air (500 L/min) is saturated with water
 vapor to increase the size of PM2.5 before the air
 is passed through five parallel virtual impactors,
each operating at 100 L/min. This increase in
 size and therefore mass ensures that particles
 have sufficient momentum to pass through the
 impactors exiting in the minor flow (5 L/min)
in which the particle concentration is enriched
 by a factor of 10- to 20-fold. Of note, particles
 < 3 µm are lost by impaction on the walls of the
 inlet and saturator and do not pass through this
 system. Similarly, particles < 15–20 nm do not
 grow in the condensation unit and are lost to
 the exhaust in the major flow from the
 impactors. The outward minor flow from the
 five impactors (25 L/min) is desaturated by sil-
ica gel dryers to restore the particles to their
 original size and diluted with filtered air before
 delivery into the human exposure chamber
 (50 L/min).

We continuously monitored the air in the
 exposure chamber for temperature, humidity,
nitrogen oxides [chemiluminescence NO-NO
 analyzer; Thermo Environmental Instruments
 (TEI), Franklin, MA, USA], carbon monoxide
 (gas filter correlation CO analyzer; TEI), sulfu-
r dioxide (pulsed fluorescence SO2 analyzer;
 TEI), and ozone (absorption ozone analyzers model
 8810; Monitor Labs, San Diego, CA, USA). We determined particle
 number using a condensation particle counter
 (Model 3022A; Thermo Systems Incorporated,
 St. Paul, MN, USA). Particle mass was continu-
 ously monitored using a DataRam nephelometer
 (Measuring Instruments for the
 Environment Corporation, Bedford, MA,
 USA) with the precise mass determined by
 gravimetric filter measurements (Teflon
 2.0 µm, 4.7 mm; PALL Life Sciences, Ann
 Arbor, MI, USA). The concentration of CAPs
 was not standardized for all subjects because
 exposures were dependent on ambient PM
 levels on the day of the study. We aimed to
deliver approximately 200 µg/m³ to allow
 comparison with previously published studies
 (Mills et al. 2005).

We used an aerosol time-of-flight mass
 spectrometer (ATOFMS; TSI) to characterize
 single particles sampled during the CAPS
 exposures. The operation of the ATOFMS
 instrument has been described in detail else-
 where (Toner et al. 2006), and detailed results
 are presented elsewhere (Freney et al. 2006).

Figure 1. A schematic diagram of the VACES used to deliver CAPs and filtered air to human subjects. Abbreviations: CO, carbon monoxide; CPC, condensation particle counter; NOx, nitrogen oxides; Q, quartz filter; RH, relative humidity; SMPS, scanning mobility particle sizer; SO2, sulfur dioxide; T, temperature; T1 and T2, teflon filters. See “Materials and Methods” for details.
Vascular studies. All subjects underwent brachial artery cannulation with a 27-gauge steel needle under controlled conditions. After a 30-min baseline saline infusion, acetylcholine at 5, 10, and 20 µg/min [endothelium-dependent vasodilator that does not release tissue plasminogen activator (t-PA); Merck Biosciences, Läufelfingen, Switzerland], bradykinin at 100, 300, and 1,000 pmol/min (endothelium-dependent vasodilator that releases t-PA; Merck Biosciences), and sodium nitroprusside at 2, 4, and 8 µg/min (endothelium-independent vasodilator that does not release t-PA; David Bull Laboratories, Warwick, UK) were infused for 6 min at each dose. The three vasodilators were separated by 20-min saline infusions and given in a randomized order. We measured forearm blood flow in the infused and noninfused arms by venous occlusion plethysmography using mercury-in-silastic strain gauges as described previously (Newby et al. 1999). We monitored supine heart rate and blood pressure in the noninfused arm at intervals throughout each study using a semiautomated, noninvasive oscillometric sphygmomanometer. For each subject, venous cannulae (17 gauge) were inserted into large subcutaneous veins of the ante-cubital fossae of both arms. Blood (10 mL) was withdrawn simultaneously from each arm at baseline and during the infusion of each dose of bradykinin, and collected into acidified blood (Stabilyte tubes; Biopool International, Ventura, CA, USA) for t-PA assays, and citrate (BD Vacutainer; Franklin Lakes, NJ, USA) for plasminogen activator inhibitor type 1 (PAI-1) assays. Samples were kept on ice and then centrifuged at 2,000 × g for 30 min at 4°C. Platelet-free plasma was decanted and stored at −80°C before assays. We determined plasma t-PA and PAI-1 antigen concentrations by ELISA (enzyme-linked immunosorbant assay kits: TintElize t-PA, Biopool International; Coaliza PAI-1, Chromogenix AB, Mölndal, Sweden). Intraassay coefficients of variation were 7.0% and 5.5% for t-PA and PAI-1 antigen, with interassay coefficients of variability of 4.0% and 7.3%, respectively. We determined hematocrit by capillary tube centrifugation at baseline and during infusion of bradykinin 1,000 pmol/min.

Blood samples were taken immediately before exposure and at 6 and 24 hr after exposure and analyzed for total cells, differential count, and platelets using an autoanalyzer. We measured serum C-reactive protein (CRP) concentrations using a highly sensitive immunonephelometric assay (Behring BN II nephelometer, Dade–Behring, Marburg, Germany). Intraassay and interassay coefficients of variability were 3.0% and 4.6%, respectively.

Exhaled breath condensate. In a pilot study, exhaled breath condensate (EBC) was collected using a Jaeger Ecoscreen (VIASYS Healthcare, Hoechberg, Germany) immediately before exposure and at 6 and 24 hr after exposures in eight healthy volunteers. Subjects rinsed their mouths with water immediately before the collection. We collected EBC during a 10-min period of normal tidal breathing through the mouthpiece with a nose clip in place. Samples were placed on ice immediately after collection and aliquoted for storage at −80°C within 30 min. We measured 8-isoprostane and nitrotyrosin in EBC using commercially available ELISA kits (Quantikine; R&D Systems, Minneapolis, MN, USA). The intraassay and interassay coefficients of variation for the assays were 5% and 6%, respectively.

Data analysis and statistics. Plethysmographic data were analyzed as described previously (Newby et al. 1999). Estimated net release of t-PA antigen was defined as the product of the infused forearm plasma flow (based on the mean hematocrit and the infused forearm blood flow) and the concentration difference between the infused and noninfused arms (Newby et al. 1997; Oliver et al. 2005). We based the sample size of 12 subjects in each group on power calculations derived from previous studies to give 90% power of detection for a 17% difference in mean t-PA release and a 22% difference in forearm blood flow at a significance level of 5% (Newby et al. 1997, 1999). Continuous variables are reported as mean ± SE. Statistical analyses were performed with GraphPad Prism (GraphPad Software, San Diego, CA, USA) using analysis of variance (ANOVA) with repeated measures, Pearson’s correlation, two-tailed Student’s t-test, or Fisher’s exact test where appropriate. The area under the curve was calculated for the estimated net release of t-PA during the forearm study period. Statistical significance was taken at p < 0.05.

Results
All patients had proven coronary heart disease with a previous myocardial infarction or stable angina treated by angioplasty and stenting (> 6 months before enrollment) and were receiving standard secondary preventive therapy (Table 1). Subjects tolerated the exposures well and did not report any symptoms during the exposure or in the 24 hr after each exposure. Patients were well matched for age and blood pressure but had greater body mass index than the healthy controls (p < 0.05).

Exposures. Ambient PM concentrations during the exposure period were variable (range, 3–174 µg/m3) across the 3-month duration of the study, with an average ambient concentration of 20 ± 4 µg/m3. Although we were able to enrich the concentration of PM 6- to 8-fold, variation in ambient levels resulted in a wide range of PM exposures between 50 and 682 µg/m3. Average PM concentrations in the CAPs exposures (190 ± 37 µg/m3) were greater than those for ambient levels and filtered air (31 ± 8 µg/m3 and 0.5 ± 0.4 µg/m3, respectively; p < 0.001). We found no significant differences between concentrations of gaseous copollutants between the filtered air or CAPs exposures (Table 2). There were, however, differences in humidity and temperature in the chamber
between the CAPs and filtered air exposures that occurred as a result of the saturation and dilution phases of the enrichment process.

Using the ATOFMS, elemental analysis of ambient PM was acquired during each 2-hr exposure for a representative 2-week period of the study. The ATOFMS detected low levels of carbon (5.3 ± 1.2% of all analysed particles) and sodium chloride (91.7 ± 6.5%) as the primary chemical constituents of ambient aerosol (Figure 2).

**Vascular function.** We observed no differences in resting heart rate, blood pressure, or baseline forearm blood flow after exposure to CAPs or filtered air in either cohort (Table 3). Bradykinin, acetylcholine, and sodium nitroprusside caused dose-dependent increases in forearm blood flow following both air and CAPs exposure ($p<0.0001$); however, this increase in blood flow was not affected by exposure to CAPs or filtered air in either patients or controls (Figure 3). Bradykinin caused a dose-dependent increase in plasma t-PA antigen concentrations ($p<0.0001$) that was similarly unaffected by exposure (Table 4). We found no correlation between peak forearm blood flow and particle mass or particle number in the CAPs exposure for any of the vasodilators infused.

**Markers of oxidative stress and inflammation.** EBC levels of 8-isoprostane, produced by oxidation of tissue phospholipids, increased 6 and 24 hr after CAPs exposure compared with exposure to filtered air (ANOVA, $p=0.04$; Figure 4), whereas levels of nitrotyrosine, an indicator of nitrosative stress, did not significantly differ between exposures. In all subjects, we observed a small increase in the number of circulating platelets (234 ± 8 vs. 225 ± 8 × 10^9/L; $p=0.007$) at 2 hr and monocytes (0.58 ± 0.03 vs. 0.53 ± 0.03 × 10^9/L; $p=0.03$) at 6 hr after exposure to CAPs compared with exposure to filtered air (Table 5). There was, however, no clear evidence of a systemic inflammatory response to CAPs exposure: Total leukocyte, neutrophil, and lymphocyte counts or serum CRP concentrations were unaltered by CAPs or air exposure at any time point.

**Discussion**

Exposure to concentrated ambient PM in a typical urban environment for 2 hr did not affect vascular vasomotor or endogenous fibrinolytic function in either middle-aged healthy volunteers or patients with coronary heart disease. The ambient PM was generally low in elemental carbon, indicating that combustion sources were not a major source of ambient particulate. However, inhalation of CAPs caused mild pulmonary oxidative stress, which did not result in a significant systemic inflammatory response. Exposure to particulate air pollution low in combustion component, at concentrations 3- to 5-fold higher than the U.S. Environmental Protection Agency (EPA) National Ambient Air Quality Standards (NAAQS; U.S. EPA 2008), is unlikely to cause adverse vascular effects capable of triggering an acute coronary event.

These findings contrast with those from our previous studies in which we reported impairment of vascular function in both healthy volunteers and patients with coronary heart disease after a 1-hr exposure to dilute diesel exhaust (Mills et al. 2005; Törnqvist et al. 2007). This apparent discrepancy requires further discussion, with differences in particle number, particle composition, and the presence of gaseous copollutants between these exposures potentially responsible.

**Ambient particle and diesel exhaust exposures.** We were able to increase the concentration of ambient PM 6- to 8-fold to deliver exposures between 50 and 682 µg/m³. The majority of exposures were substantially higher than the U.S. EPA standard of 35 µg/m³ for daily PM$_{2.5}$ (U.S. EPA 2008). Exposure to 190 µg/m³ for 2 hr is roughly comparable to a 1-hr exposure to the 300 µg/m³ of diesel...
As an important source of combustion-derived particulate, diesel exhaust is strongly implicated in the observed adverse effects of air pollution. A variable proportion of urban PM is attributable to combustion-derived nanoparticles from traffic, ranging from 20% at remote monitoring sites (Lanki et al. 2006) up to 70% in a road tunnel (Geller et al. 2005). In Edinburgh CAPs, only 5% of particles analyzed contained elemental carbon, and the principle constituent was pure, mixed, or reacted sea salts (90%). This is not surprising given Edinburgh’s maritime climate. Air-mass source attribution plots for the 5 days before arrival at the sampling location were calculated for each of the exposure periods using a

Table 3. Hemodynamic variables 6 hr after exposure in all subjects.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Exposure</th>
<th>p-Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Heart rate (beats per minute)</td>
<td>Air</td>
<td>58 ± 2</td>
</tr>
<tr>
<td></td>
<td>CAPs</td>
<td>58 ± 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.94</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>Air</td>
<td>135 ± 4</td>
</tr>
<tr>
<td></td>
<td>CAPs</td>
<td>135 ± 4</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.51</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>Air</td>
<td>78 ± 2</td>
</tr>
<tr>
<td></td>
<td>CAPs</td>
<td>78 ± 2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.96</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg)</td>
<td>Air</td>
<td>97 ± 7</td>
</tr>
<tr>
<td></td>
<td>CAPs</td>
<td>97 ± 3</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.70</td>
</tr>
<tr>
<td>Infused FBF (mL/100 mL tissue/min)</td>
<td>Air</td>
<td>2.6 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>CAPs</td>
<td>2.5 ± 0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.57</td>
</tr>
<tr>
<td>Noninfused FBF (mL/100 mL tissue/min)</td>
<td>Air</td>
<td>2.7 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>CAPs</td>
<td>2.3 ± 0.2</td>
</tr>
<tr>
<td></td>
<td></td>
<td>0.16</td>
</tr>
</tbody>
</table>

Table 4. Plasma t-PA antigen concentrations after exposure to filtered air or CAPs.

<table>
<thead>
<tr>
<th>Bradykinin (pmol/min)</th>
<th>Air</th>
<th>0</th>
<th>100</th>
<th>300</th>
<th>1,000</th>
<th>CAPs</th>
<th>0</th>
<th>100</th>
<th>300</th>
<th>1,000</th>
</tr>
</thead>
<tbody>
<tr>
<td>tPA (ng/mL)</td>
<td></td>
<td>7.6 ± 0.5</td>
<td>7.4 ± 0.5</td>
<td>7.9 ± 0.5</td>
<td>8.5 ± 0.5</td>
<td>7.2 ± 0.5</td>
<td>7.3 ± 0.6</td>
<td>7.7 ± 0.5</td>
<td>8.6 ± 0.5</td>
<td></td>
</tr>
<tr>
<td>Noninfused arm</td>
<td>7.3 ± 0.5</td>
<td>8.8 ± 0.5</td>
<td>9.7 ± 0.6</td>
<td>14.3 ± 1.2*</td>
<td>7.3 ± 0.6</td>
<td>8.6 ± 0.6</td>
<td>9.5 ± 0.7</td>
<td>14.2 ± 1.1*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infused arm</td>
<td></td>
<td>6.4 ± 0.6</td>
<td>7.5 ± 0.6</td>
<td>9.3 ± 0.7</td>
<td>14.2 ± 1.2*</td>
<td>6.3 ± 0.6</td>
<td>8.3 ± 0.6</td>
<td>9.2 ± 0.7</td>
<td>14.1 ± 1.1*</td>
<td></td>
</tr>
<tr>
<td>Difference</td>
<td>−0.4 ± 0.2</td>
<td>1.4 ± 0.4</td>
<td>1.9 ± 0.4</td>
<td>5.8 ± 1.1*</td>
<td>0.1 ± 0.2</td>
<td>1.3 ± 0.4</td>
<td>1.7 ± 0.4</td>
<td>5.7 ± 1.0*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Net t-PA release</td>
<td>−1 ± 1</td>
<td>11 ± 3</td>
<td>20 ± 5</td>
<td>90 ± 18*</td>
<td>0 ± 1</td>
<td>12 ± 4</td>
<td>24 ± 6</td>
<td>104 ± 19*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Values shown are mean ± SE (n = 24), *p < 0.0001 (ANOVA; dose response).

Figure 3. Infused and noninfused forearm blood flow in all subjects (n = 24) after CAPs and filtered air exposures during intrabrachial infusion of bradykinin (A), acetylcholine (B), and sodium nitroprusside (C). Values shown are mean ± SE. For all dose responses in the infused arm, p < 0.0001. p-Values for CAPs versus filtered air are as follows: bradykinin, p = 0.20; acetylcholine, p = 0.17; and sodium nitroprusside, p = 0.14.

Figure 4. EBC levels of 8-isoprostane (A) and nitrotyrosine (B) in healthy volunteers (n = 8) at 6 and 24 hr after exposure to CAPs or filtered air. (A) EBC levels of 8-isoprostane increased at both time points after CAPs exposure (ANOVA, p = 0.04, CAPS compared to filtered air). (B) Nitrotyrosine concentrations did not change significantly (ANOVA, p = 0.21). Values shown are mean ± SE.
U.K. Meteorological Office model (Manning et al. 2003). In all cases, air cleanly originated either predominantly from the Atlantic or the Arctic, with very little contribution from air passing over land apart from final arrival over central Scotland (Freneny et al. 2006). The proportion of airborne PM derived from remote combustion sources is likely to be low. It is likely that the absence of any detrimental vascular effects in the present study, in part, reflects the composition of Edinburgh CAPs, which are likely to be of very low toxicity. Although epidemiologic studies propose that PM mass is the metric most strongly associated with adverse events, our studies suggest that composition strongly affects potency and is likely to be the main effector of outcome.

**Air pollution, oxidative stress, and inflammation.** A substantial body of evidence supports a role for oxidative stress in determining the toxicity of ambient pollution (Donaldson et al. 2005a) and in the pro-inflammatory effects of combustion-derived particles (Donaldson et al. 2005b; Nemmar et al. 2003). Reactive oxidant species arise not only from the redox potential of the pollutants themselves but also from the activation of alveolar epithelial cells or resident macrophages and the recruitment and activation of circulating neutrophils. In the present study, we used an emerging noninvasive method of assessing pulmonary oxidative stress through collection of EBC (Montuschi et al. 1999). In the preliminary studies, we found an increase in EBC 8-isoprostane in normal subjects, suggesting that inhaled ambient particles exert a pro-oxidant effect in the airways. This is the first time, to our knowledge, this technique has been used to assess the effects of exposure to air pollutants. If these findings can be replicated and extended in a larger study, breath condensate measures may become a useful biomarker of PM exposure.

In panel and population studies, PM exposure is associated with evidence of an acute-phase response with increased CRP (Peters et al. 2001b) and plasma fibrinogen (Pekkanen et al. 2000; Schwartz 2001), enhanced plasma viscosity (Peters et al. 1997), and altered hematologic indices (Seaton et al. 1999). In animal studies, there are similar reports, with increased fibrinogen in the blood of PM-exposed hypertensive rats (Cassee et al. 2002, 2005) and normal rats exposed to ultrafine carbon particles (Elder et al. 2004). In recent years CRP has come to prominence as a biological marker of atherosclerosis, with serum CRP concentrations, even at very low levels, predicting the risk of acute myocardial infarction or stroke in apparently healthy individuals (Ridker et al. 1997). Serum CRP concentrations reflect the burden of vascular inflammation; however, in the presence of an intermittent illness or an exogenous inflammatory stimulus, serum CRP concentrations increase rapidly as part of the acute-phase response. We did not find a consistent systemic inflammatory signal after CAPs exposure: there were no changes in the numbers of circulating neutrophils, lymphocytes, or total leukocytes, even up to 24 hr. Similarly, we did not find an increase in serum CRP concentrations, suggesting that a 2-hr exposure to CAPs may not be sufficient to induce a sustained systemic inflammatory response.

The number of circulating platelets increased 2 hr after CAPs exposure, and a similar transient effect on circulating monocytes was present at 6 hr. Whether these small changes are likely to increase cardiovascular risk is questionable. The cellular mechanisms of atherosclerosis are complex, but adhesion of platelets and monocytes to the damaged arterial wall occurs early in response to vascular injury (Fuster et al. 1992). Activated platelets deposit at sites of plaque rupture and may precipitate coronary artery occlusion. Platelet—monocyte aggregates are increased in cigarette smokers (Harding et al. 2004) and in patients with unstable angina (Sarma et al. 2002), suggesting that leukocyte—platelet interactions may contribute to, or be a marker of, atheromatous plaque instability. Although we did not measure markers of platelet or monocyte activation in our study, Frampton et al. (2006) recently reported that inhalation of carbon ultrafine particles alters leukocyte expression of adhesion molecules in peripheral blood.

**Study limitations.** Using a robust randomized, double-blind sham-exposure study design, we have assessed the effect of CAPs on two complementary aspects of vascular function. Impaired vasodilation and fibrinolytic function in the forearm vascular bed have previously been shown to independently predict adverse outcomes in patients with coronary heart disease (Heitzer et al. 2001; Robinson et al. 2007), and therefore we believe this model is a reasonable surrogate for cardiovascular health. Furthermore, these studies were conducted in a highly relevant population of patients with existing coronary heart disease who are likely to be susceptible to the adverse effects of air pollution and for whom a better understanding of the effects of exposure to particulate air pollution is of clinical importance. The findings are clear: A 2-hr exposure to increased concentrations of ambient PM in an urban setting does not have significant effects on systemic vascular function.

Our findings are consistent with the only previous study of the cardiovascular effects of CAPs in humans (Brook et al. 2002); in that study, the authors assessed the effect of a 2-hr exposure to CAPs using a concentrator technology that does not enrich ultrafine particles (Sioutas et al. 1997). Flow-mediated dilation assessed by ultrasound of the brachial artery was used to determine conduit vessel function rather than venous occlusion plethysmography that measures peripheral resistance vessel function. Although CAPs exposure did not affect endothelium-dependent or independent vasodilatation in Brook et al.’s study, it did induce vasoconstriction of the brachial artery. It is possible that our CAPs exposures would have induced similar effects on conduit arterial tone because this may not be reflected in changes in basal forearm blood flow measured by venous occlusion plethysmography.

It is not possible to generalize our findings or state that exposure to PM is not likely to exert harmful vascular effects in other urban settings. This is primarily because the maritime climate and location of the MAPCEL resulted in an exposure to low levels of combustion component. The concentrator technology relies on environmental conditions on the study date to ensure that a relevant exposure is representative of PM exposure conditions. However, we did induce vasoconstriction of the brachial artery, it is possible that our CAPs exposures would have induced similar effects on conduit arterial tone because this may not be reflected in changes in basal forearm blood flow measured by venous occlusion plethysmography.

**Table 5. Systemic effects of exposure to filtered air or CAPs.**

<table>
<thead>
<tr>
<th></th>
<th>Preexposure</th>
<th>2 hr</th>
<th>6 hr</th>
<th>24 hr</th>
<th>Preexposure</th>
<th>2 hr</th>
<th>6 hr</th>
<th>24 hr</th>
<th>ANOVA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Leukocytes (× 10^9 cells/L)</strong></td>
<td>5.8 ± 0.2</td>
<td>5.8 ± 0.2</td>
<td>6.4 ± 0.2</td>
<td>5.8 ± 0.2</td>
<td>5.8 ± 0.2</td>
<td>6.1 ± 0.2</td>
<td>6.4 ± 0.2</td>
<td>5.5 ± 0.2</td>
<td>0.31</td>
</tr>
<tr>
<td><strong>Neutrophils (× 10^9 cells/L)</strong></td>
<td>3.2 ± 0.1</td>
<td>3.5 ± 0.1</td>
<td>3.9 ± 0.2</td>
<td>3.3 ± 0.1</td>
<td>3.3 ± 0.1</td>
<td>3.7 ± 0.2</td>
<td>3.9 ± 0.2</td>
<td>3.2 ± 0.2</td>
<td>0.58</td>
</tr>
<tr>
<td><strong>Lymphocytes (× 10^9 cells/L)</strong></td>
<td>1.7 ± 0.1</td>
<td>1.5 ± 0.1</td>
<td>1.7 ± 0.1</td>
<td>1.5 ± 0.2</td>
<td>1.6 ± 0.1</td>
<td>1.6 ± 0.1</td>
<td>1.8 ± 0.1</td>
<td>1.5 ± 0.1</td>
<td>0.47</td>
</tr>
<tr>
<td><strong>Monocytes (× 10^9 cells/L)</strong></td>
<td>0.57 ± 0.03</td>
<td>0.50 ± 0.03</td>
<td>0.53 ± 0.03</td>
<td>0.49 ± 0.03</td>
<td>0.55 ± 0.04</td>
<td>0.55 ± 0.04</td>
<td>0.58 ± 0.04*</td>
<td>0.50 ± 0.03</td>
<td>0.02</td>
</tr>
<tr>
<td><strong>Platelets (× 10^9 cells/L)</strong></td>
<td>221 ± 7</td>
<td>225 ± 8</td>
<td>218 ± 7</td>
<td>223 ± 7</td>
<td>224 ± 8</td>
<td>234 ± 8*</td>
<td>217 ± 6</td>
<td>228 ± 8</td>
<td>0.04</td>
</tr>
<tr>
<td><strong>CRP (mg/L)</strong></td>
<td>1.2 ± 0.2</td>
<td>1.1 ± 0.2</td>
<td>1.3 ± 0.2</td>
<td>1.3 ± 0.2</td>
<td>1.3 ± 0.2</td>
<td>1.2 ± 0.2</td>
<td>1.2 ± 0.2</td>
<td>0.72</td>
<td></td>
</tr>
<tr>
<td><strong>PA-1 antigen (ng/mL)</strong></td>
<td>57 ± 5</td>
<td>33 ± 3</td>
<td>48 ± 5</td>
<td>63 ± 5</td>
<td>34 ± 3</td>
<td>19 ± 2</td>
<td>51 ± 4</td>
<td>0.30</td>
<td></td>
</tr>
<tr>
<td><strong>t-PA antigen (ng/mL)</strong></td>
<td>10.1 ± 0.6</td>
<td>10.6 ± 0.7</td>
<td>7.2 ± 0.5</td>
<td>10.5 ± 0.7</td>
<td>7.2 ± 0.5</td>
<td>10.9 ± 0.7</td>
<td>7.2 ± 0.5</td>
<td>0.86</td>
<td></td>
</tr>
</tbody>
</table>

Values shown are mean ± SE (n = 24). Repeated-measure ANOVA CAPS versus filtered air.

*p < 0.05; Student’s t-test, CAPS versus filtered air (time point).
higher concentrations even of low toxicity CAPs would have had more potent adverse effects. Further studies in different cities and city locations are clearly warranted.

Conclusions

Despite achieving substantial increases in ambient PM concentrations in an urban setting, exposure to ambient particulate air pollution for 2 hr had no effect on vascular vasomotor or endogenous fibrinolytic function in either healthy middle-aged volunteers or patients with established coronary heart disease. These findings suggest that exposure to PM that is low in combustion component may be capable of triggering an acute coronary event.

REFERENCES


